Current treatment for advanced HCC includes mainly sorafenib and more recently approved regorafenib and nivolumab, as chemotherapy has shown little benefit. However, the modest benefit and the low response rate from systemic treatments suggest an increased need for new strategies.
Recent scientific advances hepatic cancer deaths a potential benefit from immunotherapy in hepatocellular carcinoma, due to its immunogenicity. Several trials have evaluated both immunotherapy as monotherapy and the combination with other targeted systemic treatments or local strategies.
The present article reviews current hepatic cancer deaths data regarding the possible role of immunotherapy in HCC management and future directions for clinical research.
Global cancer statistics CA Cancer J Clin ; 65 2 : Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep ; 10 1 : Known, new and emerging risk hepatic cancer deaths hepatic cancer deaths hepatocellular carcinoma review.
Presse Med ; 46 11 : Natural history of un-treated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology ; 29 1 : Medicine ; 95 11 : e Sorafenib in Advanced Hepa-tocellular Carcinoma.
N Engl J Med ; 4 : Regorafenib for patients with hepa-tocellular carcinoma who progressed on sorafenib treatment RESORCE : a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet ; 7 : Lancet ; 24 : Cell ; 7 : Cancer genome landscapes.
Meniu de navigare
Science ; : Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carci-noma. J Immunol ; 8 : Pardoll DM.
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer ; 12 4 : Hepatology ; 59 2 : Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation.
J Hepatol ; 45 2 : A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol ; 59 1 : Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
- Oxiuri perioada de incubatie
- They are also around 70 per cent more likely to be killed by cancers that affect both sexes, such as stomach, bowel and liver cancer, researchers say.
- Atunci am descoperit că femeia avea cancer la ficat.
- Squamous papilloma vocal cord icd 10
J Hepatol ; 66 3 : Gastroenterology ; 7 : Gale M, editor. PLoS Pathog ; tratamiento efectivo contra los oxiuros 2 : e A randomized hepatic cancer deaths II study to assess the effectiveness of fluid therapy or intensive nutritional support on survival in patients with advanced cancer who cannot be nourished via enteral route.
J Palliat Med ; Cancer Res ; 66 2 : Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature ; : Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology ; 64 6 :